c-di-AMP VacciGrade™

Cyclic diadenylate monophosphate - STING agonist

Cyclic diadenylate monophosphate (c-di-AMP) is a cyclic dinucleotide (CDN) produced by bacteria in which it functions as an essential second messenger [1]. It coordinates bacterial growth, cell wall stability, and responses to stress and plays a crucial role in the establishment of bacterial infection.

CDNs are a relatively new class of adjuvants that have been shown to increase vaccine potency [2]. CDNs activate innate immunity by directly binding the endoplasmic reticulum-resident receptor STING (stimulator of interferon genes), activating a signaling pathway that induces the expression of interferon-β (IFN-β) and also nuclear factor-κB (NF-κB) dependent inflammatory cytokines [3, 4].

Recent studies have also demonstrated that c-di-AMP exerts strong adjuvant activities when delivered by the mucosal route [5, 6].

c-di-AMP VacciGrade™ is a preclinical grade preparation of the cyclic dinucleotide c-di-AMP.

c-di-AMP VacciGrade™ is for research use only, not for use in humans.

Figures for this product

IRF INDUCTION (Lucia luciferase reporter)NF-kB INDUCTION (SEAP reporter)


Description: STING agonist
Synonym: Cyclic di-adenylate monophosphate, c-di-AMP sodium salt
CAS number: 54447-84-6
Formula: C20H22N10O12P2 .2Na
Molecular weight: 702.38
Purity: ≥ 95% by LC/MS
Solubility: 50 mg/ml in water
Quality: Sterile
Endotoxin Level: Lower than 0.005 EU/μg
Biological activity: Assessed by measuring induction of the interferon pathway in THP1-Blue™ ISG cells


- 1 mg of lyophilized c-di-AMP VacciGrade™
- 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

c-di-AMP VacciGrade™ is shipped at room temperature and should be stored at -20°C.


c-di-AMP VacciGrade™ is a preclinical grade preparation of the cyclic dinucleotide c-di-AMP. It is prepared under strict aseptic conditions and is tested for the presence of endotoxins. c-di-AMP VacciGrade™ is guaranteed sterile. Its endotoxin level is lower than 0.005 EU/μg.


1. Witte CE. et al., 2013. Cyclic di-AMP is critical for Listeria monocytogenes growth, cell wall homeostasis, and establishment of infection. MBio. 4(3):e00282-13.
2. Dubensky TW. et al., 2013. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Therapeutic Advances in Vaccines 1(4): 131-143.
3. Jin L. et al., 2011. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol. 187(5):2595-601.
4. Burdette DL. et al., 2011. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 478(7370):515-8.
5. Ebensen T. et al., 2011. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.Vaccine. 29(32):5210-20.
6. Škrnjug I. et al., 2014. The mucosal adjuvant cyclic di-AMP exerts immune stimulatory effects on dendritic cells and macrophages. PLoS One. 9(4):e95728.


Recent articles using InvivoGen c-di-AMP VacciGrade™


c-di-AMP VacciGrade™

Description Cyclic diadenylate monophosphate - STING agonist
Cat. Codevac-nacda
Unit Size1 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".